Best World International: Decision to Delist Custom Case Solution & Analysis

1. Evidence Brief: Best World International

Financial Metrics

Cash Position: The company reported cash and cash equivalents of 574 million Singapore dollars as of December 31, 2023.
Revenue Performance: Group revenue for fiscal year 2023 stood at 514.7 million Singapore dollars, representing a decline from 553.3 million in the previous year.
Profitability: Net profit for fiscal year 2023 was 120.4 million Singapore dollars.
Valuation Gap: The company traded at a price-to-earnings ratio significantly lower than industry peers, often cited between 5 and 7 times earnings prior to the delisting announcement.
Suspension History: Shares were suspended from trading on the Singapore Exchange for over three years, from 2019 to 2022, following short-seller allegations.

Operational Facts

Market Concentration: China remains the primary revenue driver, contributing over 80 percent of total group turnover.
Business Model Transition: Shifted from a direct selling model to a wholesale/franchise model in China to comply with local regulations and address auditor concerns.
Product Focus: Core business revolves around the DRs Secret skincare line and nutritional supplements.
Geography: Headquartered in Singapore with significant operations in Taiwan, Indonesia, and Mainland China.

Stakeholder Positions

Dora Hoan and Elizabeth Tan: Co-founders and major shareholders who control the majority of voting rights. They seek greater operational flexibility and an end to regulatory friction.
SGX RegCo: The regulatory body maintained a high level of scrutiny regarding the company's China sales and internal controls.
Minority Shareholders: Divided between those seeking a high exit premium and those concerned about the loss of transparency in a private entity.
Independent Financial Advisor: Responsible for determining if the exit offer or capital reduction terms are fair and reasonable.

Information Gaps

Franchise Transparency: The case lacks granular data on the ownership structure of the primary franchisees in China.
Future Capital Needs: No specific data provided on whether the company requires future public equity markets for expansion.
Settlement Costs: Potential hidden liabilities related to the transition from direct selling to franchising remain unquantified.

2. Strategic Analysis

Core Strategic Question

Does the regulatory burden and persistent valuation discount of the Singapore Exchange outweigh the benefits of access to public capital and institutional transparency for a China-centric business?

Structural Analysis

The company faces a structural mismatch between its operational footprint and its listing location. The regulatory environment in Singapore requires a level of disclosure regarding China-based distributors that is difficult to provide without compromising competitive secrets or violating local norms. Furthermore, the bargaining power of regulators is absolute; the three-year suspension proved that the Singapore Exchange can effectively freeze company liquidity regardless of operational profitability. The skin care market in China is maturing, and the transition to a franchise model increases the complexity of revenue recognition, further alienating conservative institutional investors in Singapore.

Strategic Options

Option 1: Selective Capital Reduction and Delisting. This involves using the 574 million Singapore dollars in cash to buy out minority shareholders. Rationale: Eliminates regulatory overhead and allows founders to manage the China transition without public scrutiny. Trade-offs: Significant cash outflow and loss of future equity financing options.
Option 2: Secondary Listing in Hong Kong. Maintain the Singapore listing but seek a dual or primary listing in Hong Kong. Rationale: Hong Kong investors have a higher appetite for China-based consumer stocks and understand the franchise model better. Trade-offs: Doubles the compliance cost and does not solve the friction with Singapore regulators.
Option 3: Status Quo with Enhanced Governance. Remain on the Singapore Exchange and appoint a global tier-one auditing firm to oversee China operations. Rationale: Preserves public status and attempts to rebuild trust. Trade-offs: Likely fails to close the valuation gap as the China risk remains a structural deterrent for Singapore investors.

Preliminary Recommendation

The company should proceed with the Selective Capital Reduction to delist. The current cash pile is unproductive and more than sufficient to fund the exit. The persistent friction with the Singapore Exchange has damaged the brand and management focus. Going private allows for a complete restructuring of the China business model away from the public eye.

3. Implementation Roadmap

Critical Path

Month 1: Formalize the Selective Capital Reduction proposal. Appoint an Independent Financial Advisor to evaluate the offer price against the net asset value.
Month 2: Secure a definitive ruling from the Singapore High Court on the classification of shareholders for the voting process.
Month 3: Convene the Extraordinary General Meeting. Success requires 75 percent approval from disinterested shareholders.
Month 4: Execute the payout and finalize the delisting. Update the corporate structure to reflect private status.

Key Constraints

Minority Opposition: A vocal 10 percent block can stall the process. The offer price must be high enough to prevent litigation but low enough to preserve company liquidity.
Cash Liquidity: While the company has 574 million Singapore dollars, a significant portion is likely held in China. Transferring these funds across borders involves regulatory hurdles and tax leakages that could delay the payout.

Risk-Adjusted Implementation Strategy

The plan assumes a smooth repatriation of funds from China. To mitigate the risk of capital controls, the company should secure a bridge loan in Singapore, using the cash held in China as collateral. This ensures the exit offer is not delayed by administrative friction in the Chinese banking system. If the shareholder vote fails, the secondary path must be an immediate pivot to a Hong Kong listing to provide liquidity to frustrated investors.

4. Executive Review and BLUF

BLUF

Best World International must exit the Singapore Exchange immediately via selective capital reduction. The regulatory environment in Singapore is fundamentally incompatible with the company’s China-dependent business model. The 574 million Singapore dollar cash reserve provides a unique window to buy out minority shareholders at a premium while the market valuation remains depressed. Remaining public serves no strategic purpose as the company is self-funding and the listing currently functions as a liability rather than an asset.

Dangerous Assumption

The analysis assumes that the cash reported on the balance sheet is fully accessible and transferable. If a significant portion of the 574 million Singapore dollars is trapped in Mainland China due to currency controls or local tax disputes, the delisting mechanism will fail, leaving the company in a worse position with an angry shareholder base.

Unaddressed Risks

Regulatory Retaliation: Delisting does not end the scrutiny of past actions. Singapore authorities may continue investigations into prior reporting periods even after the company goes private.
Operational Obscurity: Moving to a private model reduces external pressure for disciplined governance. Without public oversight, the founders may struggle to maintain the internal controls necessary to manage a complex franchise network in China.

Unconsidered Alternative

The team failed to consider a partial divestment of the China business unit. By selling a 40 percent stake in the China operations to a local private equity firm, the company could have unlocked immediate value, validated its sales figures through third-party due diligence, and remained public in Singapore with a de-risked balance sheet.